Article info
PDFCommentary
Challenges of economic evaluation in rare diseases
- Correspondence to Dr Stephen Duckett, Religion and Social Policy Network, University of Divinity, Victoria, Victoria, Australia; stephen.j.duckett{at}gmail.com
Citation
Challenges of economic evaluation in rare diseases
Publication history
- Received December 14, 2021
- Accepted December 21, 2021
- First published January 21, 2022.
Online issue publication
January 22, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Does NICE apply the rule of rescue in its approach to highly specialised technologies?
- Donor blood screening and moral responsibility: how safe should blood be?
- Public healthcare resource allocation and the Rule of Rescue
- The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
- Should rare diseases get special treatment?
- Modelling the cost-effectiveness of essential and advanced critical care for COVID-19 patients in Kenya
- Economic evaluations of fall prevention exercise programs: a systematic review
- Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis
- Validating the rigour of adaptive methods of economic evaluation
- Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China